Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.

@article{Island2009SuccessfulTW,
  title={Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.},
  author={Eddie R. Island and Ignacio M Gonzalez-Pinto and Hin-Lin Tsai and Phillip Ruiz and Panagiotis Tryphonopoulos and Monica L Gonzalez and Juan Pablo Solano and Marie Rossique and Gennaro Selvaggi and Akin Tekin and Lesley J. Smith and Andreas G. Tzakis},
  journal={Clinical transplants},
  year={2009},
  pages={465-9}
}
Graft rejection is a serious complication after intestinal and multivisceral transplantation. Classic anti-rejection strategies often focus on addressing the cellular component, however mounting evidence suggests that antibody mediated rejection may also play an important role in patient and graft survival. Bortezomib, a proteasome inhibitor used in the… CONTINUE READING